Axsome Stock Jumps After Snagging Priority Review For Depression DrugInvestors Business Daily • 04/26/21
Axsome Therapeutics Stock Jumps As FDA Accepts AXS-05 Application In Major Depressive DisorderBenzinga • 04/26/21
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive DisorderGlobeNewsWire • 04/26/21
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/01/21
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock OptionsZacks Investment Research • 01/07/21
Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer's Disease AgitationGlobeNewsWire • 12/31/20
Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of MigraineGlobeNewsWire • 12/31/20
Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal IdeationGlobeNewsWire • 12/08/20
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant DepressionGlobeNewsWire • 12/02/20
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive DisorderGlobeNewsWire • 12/01/20